Harvard Bioscience, Inc.
| Security | HBIO / Harvard Bioscience, Inc. |
| Insider | Jennifer Cote |
This page shows the track record and history of Cote Jennifer
insider trades in Harvard Bioscience, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.
It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean
it is illegal for them to make any
trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Jennifer Cote in HBIO / Harvard Bioscience, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Max |
Price at Max |
Max Profit ($) |
Max Return (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Jennifer Cote in HBIO / Harvard Bioscience, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Transaction History
| File Date |
Trade Date |
Form | Insider | Ticker | Security Title | Code | Direct | Exercise Price |
Unit Price |
Units Changed |
Value Changed (1K) |
Remaining Options |
Remaining Shares |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-21 | 2025-03-19 | 4 | Cote Jennifer | HBIO | Common Stock | D | 0.6886 | -5,687 | -4 | 159,019 | ||||
| 2024-12-31 | 2024-12-29 | 4 | Cote Jennifer | HBIO | Common Stock | D | 1.9800 | -3,797 | -8 | 160,210 | ||||
| 2024-12-31 | 2024-12-29 | 4 | Cote Jennifer | HBIO | Common Stock | D | 1.9800 | -4,731 | -9 | 164,007 | ||||
| 2024-03-07 | 2024-03-06 | 4 | Cote Jennifer | HBIO | Common Stock | D | 4.1100 | -9,920 | -41 | 168,738 | ||||
| 2024-03-07 | 2024-03-05 | 4 | Cote Jennifer | HBIO | Common Stock | D | 35,800 | 178,658 | ||||||
| 2024-03-07 | 2024-03-05 | 4 | Cote Jennifer | HBIO | Common Stock | D | 35,800 | 178,658 | ||||||
| 2024-01-03 | 2023-12-29 | 4 | Cote Jennifer | HBIO | Common Stock | D | 5.3500 | -2,631 | -14 | 107,058 | ||||
| 2024-01-03 | 2023-12-29 | 4 | Cote Jennifer | HBIO | Common Stock | D | 5.3500 | -3,279 | -18 | 109,689 | ||||
| 2023-03-08 | 2023-03-06 | 4 | Cote Jennifer | HBIO | Common Stock | D | 29,880 | 112,968 | ||||||
| 2023-03-08 | 2023-03-06 | 4 | Cote Jennifer | HBIO | Common Stock | D | 25,862 | 83,088 | ||||||
| 2023-03-08 | 2023-03-06 | 4 | Cote Jennifer | HBIO | Common Stock | D | 26,892 | 57,226 | ||||||
| 2023-01-03 | 3 | Cote Jennifer | HBIO | Common Stock | D | 30,334 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
